Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › ponatinib

ponatinib

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of ponatinib

9 trials tracked of ponatinib.

9Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 8 Other / NA 1
  1. Phase 2 Ponatinib in Advanced NSCLC w/ RET Translocations Completed
  2. Phase 2 Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma Completed
  3. Phase 2 Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) Completed
  4. Phase 2 Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses Completed
  5. Phase 2 Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT. Completed
  6. Phase 2 Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers Completed
Show 3 more trials
  1. Phase 2 Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions Completed
  2. Phase 2 A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Completed
  3. N/A Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database Completed

Showing the 9 most-cited and recently-updated of 9 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Chemotherapy-Free Ponatinib Plus Blinatumomab Beats Imatinib in Ph-Positive ALL
Oncology RCT
Chemotherapy-Free Ponatinib Plus Blinatumomab Beats Imatinib in Ph-Positive ALL Trial shows ponatinib and blinatumomab improve outcomes for Philadelphia-positive ALL
In Ph-positive ALL, frontline ponatinib plus blinatumomab achieved 86% 24-month event-free survival versus 67% with imatinib plus chemothera…
A new combination of ponatinib and blinatumomab showed higher survival rates and fewer relapses for adults with Philadelphia-positive ALL.
Oct 15, 2026
Case report on asciminib plus ponatinib or axitinib in CML relapse with B lymphoblastic blast crisis
Oncology
Case report on asciminib plus ponatinib or axitinib in CML relapse with B lymphoblastic blast crisis New combo drug stops leukemia that fought back against two drugs
This case report describes a single CML patient who relapsed with B lymphoblastic blast crisis harboring a T315I mutation and a novel e6a3 B…
A new three-drug mix stops a tough leukemia that grew stronger after two drugs failed to control it.
medRxiv Apr 24, 2026
Ponatinib in CP-CML resistant to prior TKI or T315I mutation showed molecular response at Month 12
Oncology Phase II
Ponatinib in CP-CML resistant to prior TKI or T315I mutation showed molecular response at Month 12 Ponatinib doses show early signs in resistant chronic myeloid leukemia patients
This Phase 2 study evaluated ponatinib in 283 participants with chronic-phase chronic myeloid leukemia (CP-CML) resistant to prior tyrosine-…
Ponatinib at three daily doses showed early signs of helping resistant chronic myeloid leukemia patients reach a key molecular response goal…
CT.gov Apr 9, 2026